Study points to potential cause for “chemo brain”

Korean researchers find CRC patients over 70 years don’t stand to benefit from chemo

Oxaliplatin-based chemotherapy significantly improves survival only in stage 3 colorectal cancer patients aged 70 or younger, according to a study conducted by researchers at Korea University Guro Hospital and Korea University College of Medicine. For patients over 70, the drug offered no survival advantage and led to higher rates of treatment discontinuation due to toxicity.

September 26, 2025

Vol.51 No.35

Clinical Roundup

MammaPrint predicts chemotherapy benefit in HR+HER2 early breast cancer patients, observational FLEX study finds

The MammaPrint, a gene expression profiling test, predicts the benefit of chemotherapy for patients with hormone receptor-positive, HER2-negative early-stage breast cancer, according to findings published in JNCI Cancer Spectrum.

September 05, 2025

Vol.51 No.32

Clinical Roundup

Tagrisso + chemo improve OS in EGFR-mutated advanced lung cancer, phase III trial shows

Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial.

July 25, 2025

Vol.51 No.29

Clinical Roundup

Sequences of cancer treatments affect patient outcomes and healthcare costs, UC Irvine-led study shows

Specific sequences of chemotherapy, targeted therapy, and immunotherapy yielded significantly different results, according to a study that utilized simulation models and real-world data to predict outcomes under different sequencing scenarios.

July 18, 2025

Vol.51 No.28

Clinical Roundup

Neoadjuvant ablative radiotherapy + chemo reduces risk of pancreatic cancer regrowth, stimulates immune system, cohort study finds

Adding targeted radiation to chemotherapy prior to surgery may offer better control of pancreatic tumors—potentially reducing the rate of recurrence after treatment, according to a cohort study from Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center.

July 11, 2025

Vol.51 No.27

Clinical Roundup

Neoadjuvant immunotherapy + chemo regimen significantly improves long-term survival in NSCLC

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer improved long-term survival overall compared with chemotherapy alone, according to a clinical trial published June 2 in The New England Journal of Medicine and presented at the annual meeting of the American Society of Clinical Oncology.

June 06, 2025

Vol.51 No.22

Study points to potential cause for “chemo brain”

YOU MAY BE INTERESTED IN

Korean researchers find CRC patients over 70 years don’t stand to benefit from chemo

MammaPrint predicts chemotherapy benefit in HR+HER2 early breast cancer patients, observational FLEX study finds

Tagrisso + chemo improve OS in EGFR-mutated advanced lung cancer, phase III trial shows

Sequences of cancer treatments affect patient outcomes and healthcare costs, UC Irvine-led study shows

Neoadjuvant ablative radiotherapy + chemo reduces risk of pancreatic cancer regrowth, stimulates immune system, cohort study finds

Neoadjuvant immunotherapy + chemo regimen significantly improves long-term survival in NSCLC

Renew today!

Subscriber content

Never miss an issue!

Login